All conditions

Polymyalgia Rheumatica

Plain English clinical trial information, updated daily from ClinicalTrials.gov and public government registries. Not medical advice.

85
Trials on record
15
Recruiting now
0
Australian sites
3
Phase 3 trials
How these figures are counted
  • Trials on record is every trial tagged to this condition at any stage, except those withdrawn before starting or terminated early. Most are completed rather than ongoing, so this is a measure of research history, not of current activity. It is also smaller than the sitewide "trials tracked" figure, which does include withdrawn and terminated trials.
  • Recruiting now counts only trials whose registry status is "Recruiting". Trials listed as not yet recruiting or enrolling by invitation are excluded, so this understates how many may open to new participants soon.
  • Australian sites counts trials counted under "Recruiting now" that list at least one Australian site. A site being listed does not mean it is currently enrolling, and Australian trials registered only on ANZCTR are not counted yet, so this understates local availability.
  • Phase 3 trials counts trials counted under "Recruiting now" that are at Phase 3.

Find recruiting trials for Polymyalgia Rheumatica →

Get alerts when Polymyalgia Rheumatica trials change ↗

Voxsanity currently covers 103 conditions. We are expanding coverage regularly.

Understanding Polymyalgia Rheumatica

Polymyalgia Rheumatica (often called PMR) is a condition that causes pain, stiffness, and aching in the muscles around the shoulders, neck, upper arms, hips, and thighs. The stiffness is often worst in the morning and can make everyday tasks like getting dressed, raising your arms, or getting up from a chair quite difficult. Despite how uncomfortable it feels, PMR does not directly damage the muscles or joints themselves. Doctors believe it is caused by inflammation in the body, though the exact reason this happens is not fully understood.

PMR is one of the more common inflammatory conditions seen in older Australians. It almost always affects people over the age of 50, and the average age at diagnosis is around 70. It is more common in women than men, and tends to occur more frequently in people of Northern European background, though it can affect anyone. Across Australia, thousands of people are living with this condition, so you are far from alone in receiving this diagnosis.

The good news is that PMR generally responds well to treatment. The usual approach involves medication to reduce the inflammation in the body, which tends to bring significant relief from symptoms fairly quickly for most people. Treatment is typically managed over a period of months to years, with regular check-ins with a doctor to monitor how things are going and adjust the plan as needed. A GP or specialist such as a rheumatologist will work with you to find the right approach for your individual situation. It is a good idea to ask your healthcare team any questions you have, so you feel informed and comfortable with your care.

This overview is an AI generated summary written from public medical sources and checked on a sample basis. It is general information, not medical advice or a diagnosis. Always speak with your doctor about your situation. How we use AI

Can you access treatment for Polymyalgia Rheumatica in Australia right now? Here's what's publicly known.

  • No PBS-subsidised medicines are currently mapped for Polymyalgia Rheumatica on Voxsanity. Your doctor or pharmacist can advise on what may be available.
  • No trials currently recruiting at Australian sites right now. Worldwide trials may still be an option. See the trial list below.

Information on this site does not constitute medical advice. Data is sourced from publicly available government registries. Always consult your doctor before making any health decisions. Trial status should be verified directly with the trial site.

Updated regularly from public government registries

Research pipeline

Where trials for Polymyalgia Rheumatica currently sit in the development pipeline. The funnel shape shows how few drugs reach later phases in general; the counts are this condition's actual trial numbers.

Phase success rates are industry-wide historical averages, not predictions for specific trials. Learn how trials work →

Most active research sponsors

Organisations with the most recruiting trials for Polymyalgia Rheumatica.

View sponsor profile
View sponsor profile
View sponsor profile

Where trials are running

Clinical trial sites for Polymyalgia Rheumatica by country. Australia is highlighted.

Showing the top 10 of 24 countries with trial sites.

Clinical trials for Polymyalgia Rheumatica

Showing 17 of 17 trials

The plain English eligibility text on each trial below is an AI generated summary of the official criteria, checked on a sample basis. How we use AI

🇦🇺 NCT03600818 · Sanofi Phase 3 · 17 countries Terminated
Terminated Phase 3 Est. completion 19 May 2021
🇦🇷 AR🇦🇺 AU🇧🇪 BE🇨🇦 CA🇪🇪 EE🇫🇷 FR🇩🇪 DE🇭🇺 HU +9 more

**Who might be able to join this trial:** - You have been diagnosed with Polymyalgia Rheumatica (PMR) using recognised international diagnostic standards. - You are currently taking prednisone (a steroid) at a dose of at least 7.5 mg per day but no more than 20 mg per day at the time of screening. - You are willing an...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT04972968 · AbbVie Phase 2 · 15 countries Terminated
Terminated Phase 2 Est. completion 24 July 2023
🇦🇺 AU🇦🇹 AT🇨🇦 CA🇫🇷 FR🇩🇪 DE🇭🇺 HU🇮🇹 IT🇯🇵 JP +7 more

**Who might be able to join this trial:** - You have been diagnosed with a condition called Polymyalgia Rheumatica (PMR) and meet a specific set of recognised criteria used to confirm this diagnosis. - You have had at least 2 clear episodes where your PMR symptoms have flared up (come back or gotten worse). - You are c...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT01241305 · University of Pennsylvania Not Applicable · 3 countries Recruiting
Recruiting Not Applicable Est. completion 1 August 2028
🇨🇦 CA Turkey (Türkiye)🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with Giant Cell Arteritis (GCA) — a condition affecting blood vessels in the head — and were over 50 years old when symptoms began, along with certain signs such as new head pain, a tender or weak pulse in the temple artery, abnormal blood test result...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04474847 · University of Pennsylvania Phase 3 · 2 countries Recruiting
Recruiting Phase 3 Est. completion 1 December 2029
🇨🇦 CA🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with giant cell arteritis (GCA) — either for the first time or as a returning condition — and who meet at least 3 out of 5 specific diagnostic criteria (including at least one involving a temporal artery exam or biopsy/imaging result) - People...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05193396 · Marianne Andersen Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 January 2026
🇩🇰 DK

**Who might be able to join this trial:** - You are 50 years of age or older - You have been diagnosed with Polymyalgia Rheumatica (PMR) or Giant Cell Arteritis (GCA) — two conditions causing inflammation — and are currently in remission (no active symptoms) without steroid tablets, for more than 2 weeks but less than...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT05749094 · Centre Integre Universitaire de Sante et Services Sociaux du Nord de l... Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2027
🇨🇦 CA

**Who might be able to join this trial:** - You are over 50 years old. - You have been referred to a GCA (Giant Cell Arteritis) clinic because doctors suspect you may have this condition for the first time. - You are able to understand the study information and are willing to sign a consent form agreeing to take part....

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06172361 · Zhejiang University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 30 September 2025
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with Polymyalgia Rheumatica (PMR) based on recognized medical criteria - You have not taken steroids or biological medications in the 2 weeks before joining the study - Your PMR is currently highly active, based on a standard disease activity score abo...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06609668 · Centre Hospitalier Universitaire Dijon Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2027
🇫🇷 FR

**Who might be able to join this trial:** - You have agreed to take part and given your verbal consent - You are over 50 years old - You were over 50 years old when your symptoms first started - You have pain and inflammation around the shoulders and/or hips (the large joints connecting your limbs to your body) - Your...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06647134 · M.D. Anderson Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 March 2028
🇺🇸 US

Who might be able to join this trial: - You are 18 years of age or older - You can speak and understand English well enough to have a conversation and agree to take part in the study - You have been diagnosed by a specialist doctor (rheumatologist) with a joint inflammation condition or a muscle/artery inflammation con...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06894602 · University Hospital, Brest Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2028
🇫🇷 FR

Who might be able to join this trial: - You must be an adult (18 years of age or older) - You must have been diagnosed with giant cell arteritis according to the ACR 2022 medical guidelines - You must not have objected to taking part in the study Who may not be able to join: - People who are unable to understand how t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07001059 · Hôpital NOVO Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 March 2028
🇫🇷 FR

Who might be able to join this trial: - You are suspected to have a condition called GCA (Giant Cell Arteritis), meaning your doctor thinks you may have it but it has not been confirmed yet - You are over 50 years old Who may not be able to join: - You have previously been diagnosed with GCA (Giant Cell Arteritis) - Y...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07010484 · Kresten Krarup Keller Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 August 2028
🇩🇰 DK

**Who might be able to join this trial:** - You are being seen at a rheumatology or internal medicine department in one of these locations: Aarhus, Silkeborg, Horsens, Gødstrup, Randers, or Svendborg, and doctors suspect you may have a condition called PMR (polymyalgia rheumatica) - You are over 50 years old - You have...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07060274 · Centre Hospitalier le Mans Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2028
🇫🇷 FR

**Who might be able to join this trial:** - People aged 50 or older - People who are not under any form of legal guardianship or protection - People who have been diagnosed with Giant Cell Arteritis (GCA) according to the 2022 ACR classification criteria, and who also have a specific finding called a "halo sign" — see...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07138898 · NYU Langone Health Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 January 2028
🇺🇸 US

**Who might be able to join this trial:** - Adults who are 18 years of age or older at the time of signing the consent form - People who have been diagnosed with a rheumatic disease, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, lupus (SLE), juvenile idiopathic arthritis, spondyloarthriti...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07279688 · University Hospital, Brest Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 November 2028
🇫🇷 FR

**Who might be able to join this trial:** - You are at least 50 years old. - You have been diagnosed with a condition called Polymyalgia Rheumatica (PMR), either newly diagnosed or in a form that has not responded well to previous treatment. - You are either not taking steroid medications (corticosteroids), or you are...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07286214 · Sanofi Phase 4 · 2 countries Recruiting
Recruiting Phase 4 Est. completion 4 June 2029
🇨🇦 CA🇺🇸 US

**Who might be able to join this trial:** - Adults aged 50 or older who have been diagnosed with a condition called polymyalgia rheumatica (PMR), based on recognised medical guidelines - People who are either newly diagnosed with PMR (and have taken steroid tablets for no more than 6 weeks), or who have had an early re...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT07552636 · University of Aarhus Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2028
🇩🇰 DK

**Who might be able to join this trial:** - You have been diagnosed with a condition called Giant Cell Arteritis (GCA) by a specialist doctor (rheumatologist), confirmed by a scan or tissue sample taken within the last 3 years. - Your GCA is currently under control (in remission), meaning you have been following your t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Advocacy and support in Australia

Organisations that can offer information, support, or connection for Polymyalgia Rheumatica. Where more than one is listed, they serve different needs or regions, so choose whichever fits your situation.

Polymyalgia rheumatica is covered by Arthritis Australia as a related musculoskeletal condition.

This is a starting point, not medical advice or an endorsement. Contact details change; search the organisation name to find its current website.